NYSE American: IGC | Advancing Alzheimer's research through therapeutic innovation and AI investor.igcpharma.com/
Maryland, US.
- Tweets 2,598
- Following 205
- Followers 1,118
- Likes 178
More than 55 million people worldwide are living with Alzheimer's disease
This World Alzheimer's Day, we recognize everyone affected by the disease and reaffirm our commitment to advancing Alzheimer's research
#WorldAlzheimersDay
1
3
591
Blood biomarkers are becoming an important area of Alzheimer's research
The most widely studied include:
• p-tau
• Amyloid-beta (Aβ)
• Neurofilament light (NfL)
Each provides researchers with different insights into the biology of Alzheimer's disease
#AlzheimersResearch
1
3
488
Women represent a disproportionate share of people living with Alzheimer's disease
Researchers continue to investigate how factors such as longevity, hormonal changes, genetics, and brain biology may contribute to this disparity
#AlzheimersDisease #WomensHealth
1
278
Advancing Alzheimer's research requires more than a single area of expertise
By bringing together diverse scientific disciplines, researchers can deepen our understanding of the disease and help drive future discoveries
#AlzheimersResearch #Neuroscience
4
537
MYTH vs. FACT: Alzheimer's Disease
There's a lot of misinformation about Alzheimer's disease. Let's separate fact from fiction with evidence-based insights
🧵↓
#AlzheimersDisease #BrainHealth
1
2
118
Myth 3: Nothing can be done after an Alzheimer's diagnosis.
Fact: While there is no cure, an early diagnosis can help people access treatment options, supportive care, and resources that may improve quality of life.
Source: National Institute on Aging (NIA)
1
34
Reliable information helps individuals, families, and caregivers make informed decisions about brain health.
Learn more through trusted organizations like the Alzheimer's Association and the National Institute on Aging.
#AlzheimersDisease
22
Alzheimer's disease is a global challenge, but its impact is not experienced equally around the world
Research across diverse populations is helping deepen our understanding of the factors that influence disease outcomes
Read more: igcpharma.com/alzheimers-acr…
#AlzheimersDisease
5
876
As CALMA approaches enrollment closure and expected Q4 topline readout, IGC Pharma is strengthening its regulatory readiness in preparation for potential engagement with the FDA and EMA
Read more: finance.yahoo.com/healthcare…
#AlzheimersResearch #ClinicalTrials #IGCPharma
2
337
@IGCPharma is 8 patients away from completing enrollment in its Phase 2 CALMA #Alzheimer’s trial.
The Company is strengthening its regulatory, biostatistical, AI-enabled data science, and strategic pharmaceutical development capabilities as IGC-AD1 advances toward expected Phase 2 topline results in the fourth quarter of 2026.
Read more: igcpharma.com/igc-pharma-str…
5
412
Changes in memory are among the most recognized symptoms of Alzheimer's disease, but they're not the only ones
Understanding the full range of symptoms can help foster greater awareness of the disease and its impact on patients and caregivers
#AlzheimersResearch #BrainHealth
1
2
502
Following the federal jury verdict in United States v. Andrew Left, IGC Pharma announced that it is evaluating potential civil remedies.
Read more: finance.yahoo.com/healthcare…
#NYSEAmerican #IGCPharma
3
590
Why is Alzheimer's disease so difficult to treat?
One reason is that Alzheimer's isn't driven by a single biological process. It involves multiple changes in the brain that scientists are still working to understand ↓
#AlzheimersResearch #Neuroscience
1
1
110
Because Alzheimer's involves multiple biological processes, researchers are exploring different therapeutic strategies
No single approach addresses every aspect of the disease, making continued research essential
1
28
That's a wrap on #AAIC2026!
Proud of our AI team for presenting AI-driven research and demonstrating aha™ in connection with the Alzheimer's Disease Data Initiative's (@AlzData) AD Workbench ecosystem
Thank you to everyone who connected with us in London
#AlzheimersResearch
1
2
144
The IGC Pharma AI team is in London for #AAIC2026 (@alzassociation), presenting research on AI, digital biomarkers, multimodal data integration, and data harmonization for Alzheimer's disease
Proud to contribute to the global Alzheimer's research community
#AlzheimersResearch
1
148